content_top
34 companies, 1 interpreter! Insight, foresight
and recommendation 

Adverum Biotechnologies (ADVM)

0
-0.80
(-80.00%)
 Nov 10, 12:45PM EST
content_middle

A clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration and diabetic retinopathy; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.

The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five ophthalmic indications; Regeneron Pharmaceuticals, Inc.; and GenSight Biologics S.A. to develop gene therapy products to deliver certain therapeutic transgenes.

Company Website
Previous Close: 
10.19
Open: 
N/A
Bid: 
N/A
Ask: 
N/A
1yr Target Price: 
9.50
Day's Range: 
N/A - N/A
52wk Range: 
7.10 - 29.70
Volume: 
592976
Average Daily Volume: 
328335
Market Capitalization: 
0.00M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
0.00M
content_right

Pages